HNN3.0

Project cooperationUpdated on 12 December 2025

LNP delivery with barcoded mRNA

Professor at Ghent University

Ghent, Belgium

About

We offer expertise in lipid nanoparticle (LNP) delivery using barcoded mRNA payloads to enable high-throughput, quantitative evaluation of mRNA delivery and expression. By embedding short, inert nucleotide barcodes within the mRNA (typically in the 3′ UTR), multiple LNP formulations can be administered simultaneously and resolved post-delivery by sequencing.

This approach allows researchers to directly link LNP composition to biodistribution, cell-type uptake, and functional expression using bulk or single-cell RNA sequencing. It supports parallel screening of large LNP libraries in a single experiment, reducing time, cost, and biological variability compared with one-by-one testing.

Our knowledge covers library design, LNP formulation strategies, in vivo and in vitro delivery, and sequencing-based analysis (bulk, single-cell, and spatial) pipelines. This enables rational optimization of LNPs for specific tissues or cell types and accelerates development of mRNA vaccines, gene regulation tools, and therapeutic candidates.

Topic

  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)

Type

  • Partner seeks Consortium/Coordinator

Organisation

Ghent University

University

Ghent, Belgium

Similar opportunities

  • Project cooperation

    Medical education collaboration

    • Consortium/Coordinator seeks Partners
    • Partner seeks Consortium/Coordinator
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
    • DESTINATION 1: HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life sciences
    • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)

    Luca Takács

    Founder and CEO at LNP Academy

    Budapest, Hungary

  • Project cooperation

    GeneCore: Advanced Transcriptomics (Single-cell/Spatial) & High-Throughput Screening Partner

    • Partner seeks Consortium/Coordinator
    • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways

    Lukáš Valihrach

    Head of Core Facility at Institute of Biotechnology of the Czech Academy of Sciences

    Vestec, Czech Republic

  • Project cooperation

    Translational immunologist with wet lab and dry lab in-house expertise

    Benson Ogunjimi

    Associate Professor at University of Antwerp

    Antwerp, Belgium